ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis
A live, multi-source view of ACADIA Pharmaceuticals Inc. (ACAD): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial.
Sector: Healthcare · Industry: Biotechnology · United States · 796 employees · acadia.com
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, ACADIA Pharmaceuticals Inc. (ACAD) last closed at $28.02 (the last completed close before that scan).
Technicals at the scan: RSI 47 (neutral territory), price -4.0% versus its 20-day average, 20-day versus 50-day average spread +7.0%, MACD histogram -0.34.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 73/100.
Next scheduled company event: in 57 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of ACAD; corporate insiders filed 0 buys and 3 sells (1 filer, latest disclosure 2026-08-07). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Mark C. Schneyer (0B/3S). Who is trading what
RapidTradeView pick record
ACAD has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls ACADIA Pharmaceuticals Inc. (ACAD) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell ACAD.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.